Compare American Homes 4 Rent Class A (AMH) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Amphastar Pharmaceuticals Inc — how do they compare? American Homes 4 Rent Class A trades at $33.92 (market cap $12.28B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: American Homes 4 Rent Class A is far larger — about 14.2× Amphastar Pharmaceuticals Inc's market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMH | AMPH | |
|---|---|---|
Market Cap | $12.28B | $863.95M |
Sector | Real Estate | Health |
52-Week High | $35.82 | $30.81 |
52-Week Low | $27.38 | $16.87 |
Enterprise Value | $17.35B | $1.26B |
Dividend Yield | 3.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $34.63, up 0.23% with strong technical momentum and bullish moving averages. The REIT demonstrates robust fundamentals with consistent revenue growth from $1.5B in 2022 to $1.85B in 2025, net income margin expansion to 25.53%, and three consecutive quarterly EPS beats. Recent Q2 2026 results exceeded FFO estimates, prompting raised full-year guidance. Institutional activity shows mixed positioning while analyst consensus remains positive with a $36.45 price target.
AMH presents a compelling opportunity with strong operational execution in the single-family rental market, though investors face risks from regulatory changes affecting institutional home ownership and elevated debt levels. The stock's current valuation at 27.48 P/E appears reasonable given growth trajectory, but monitoring legislative impacts and interest rate sensitivity remains crucial for sustained performance.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
